Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission (EC), which has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera's marketing authorization application (MAA) for vimseltinib. This decision is expected in the second quarter of the fiscal year ending March 31, 2026.
'CHMP's positive opinion is an important milestone for the TGCT community in the European Union (EU), where there are currently no approved treatments for TGCT, and for vimseltinib, which is now one step closer to potential EU regulatory approval,' said Ryota Udagawa, President and Chief Executive Officer of Deciphera. 'We look forward to building upon vimseltinib's positive CHMP opinion as we work to bring this medicine to TGCT patients around the world in need of new treatment options.'
The positive CHMP opinion is supported by compelling efficacy and safety results from the pivotal Phase 3 MOTION study of vimseltinib in patients with TGCT not amenable to surgery with no prior anti-CSF1/CSF1R therapy (prior therapy with imatinib or nilotinib allowed), compared to placebo, as well as the Phase 1/2 study of vimseltinib. In MOTION, vimseltinib demonstrated a statistically significant and clinically meaningful objective response rate (ORR) at Week 25 in the intent-to-treat (ITT) population, as assessed by blinded independent radiologic review (BIRR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), versus placebo (40% in vimseltinib arm vs 0% in placebo arm, p <0.0001). The primary endpoint was supported by statistically significant and clinically meaningful improvements in active range of motion, patient-reported physical functioning, and patient-reported pain observed in the vimseltinib arm compared to the placebo arm at week 25. The safety profile of vimseltinib is manageable and consistent with results previously disclosed in the Phase 1/2 clinical trial.
About vimseltinib
Vimseltinib is an oral switch-control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R. Vimseltinib has been developed using Deciphera's proprietary switch-control kinase inhibitor platform. ROMVIMZA™ (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
About Tenosynovial Giant Cell Tumor (TGCT)
TGCT is caused by a translocation in colony-stimulating factor 1 (CSF1) gene resulting in overexpression of CSF1 and recruitment of colony-stimulating factor 1 receptor (CSF1R)-positive inflammatory cells into the lesion. TGCT is a rare, non-malignant tumor that develops inside or near joints. TGCT is caused by dysregulation of the CSF1 gene leading to overproduction of CSF1. TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS), a diffuse-type of TGCT. TGCT is a locally aggressive neoplasm that can grow and cause damage to surrounding tissues and structures inducing pain, swelling, and limitation of movement of the joint. Surgery is the main treatment option; however, these tumors tend to recur, particularly in diffuse-type TGCT. If untreated or if the tumor continually recurs, damage and degeneration may occur in the affected joint and surrounding tissues, which may cause significant disability. For a subset of patients, surgical resection will potentially cause worsening functional limitation or severe morbidity, systemic treatment options are limited and a new therapeutic option for TGCT is needed.
About Deciphera Pharmaceuticals, LLC
Deciphera, a member of Ono Pharmaceutical Co., Ltd., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Deciphera is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from Deciphera's platform in clinical studies, QINLOCK ® (ripretinib) is Deciphera's switch-control kinase inhibitor approved in many countries including the European Union and the United States for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ROMVIMZA™ (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of 'Dedicated to the Fight against Disease and Pain,' Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.
Cautionary Note Regarding Forward-Looking Statements
In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Britain set for minor boost as world economy growth forecast upgraded despite Trump tariffs
The world economy will grow faster than expected after the impact of Donald Trump's tariff war waned and imports to the US surged, new projections show. Britain is in line for a small boost with the IMF upgrading its growth predictions by just 0.1 per cent for 2025. Growth is expected to sit at 1.2 per cent this year and 1.4 per cent for 2026, the International Monetary Fund's (IMF) latest World Economic Outlook forecasts. It came as the IMF said the global economy would be more resilient than it expected in May. Global growth is set to be 3 per cent this year and 3.1 per cent next year, up from 2.8 per cent and 3 per cent respectively. Like Britain, Germany and Italy have both had their growth upgraded by 0.1 per cent for 2025, and received no upgrade for 2026. Meanwhile, Canada was handed a marginally bigger upgrade of 0.2 per cent in 2025 and 0.3 per cent in 2026, taking its growth to 1.6 per cent in 2025 and 1.9 per cent in 2026. The world growth upgrade reflects what the IMF called front-loading in recent months, with countries rushing to ship goods to the US to get ahead of Mr Trump's tariffs. This has happened as businesses and households tried to prepare for planned increases to US tariff rates, following Mr Trump's "liberation day" announcements in April, according to the report. The IMF said front-loading had "shaped economic activity in the first half of the year", adding that it was "creating exposures that could amplify the impact of any potential negative shocks". For example, firms could end up having too much stock, therefore pushing down future imports, or it could lead to additional holding costs or the risk of items becoming obsolete. Meanwhile, the growth upgrade since April was also driven by US tariffs being lowered since higher rates were first announced by Mr Trump, alongside improved conditions in the financial markets. This came after the US struck new trade deals, including with the UK and, most recently, the EU. But the UK's growth rate flatlining while trade deals benefited other economies poses fresh questions for Rachel Reeves. The chancellor has been accused of stalling growth with her and Sir Keir Starmer's economic doom and gloom after taking office last July and through October's tax-hiking Budget. She has a multi-billion pound black hole to fill ahead of this autumn's Budget and is considering a range of potential tax hikes and spending cuts to balance the country's books. The Conservatives said under Labour 'growth is going nowhere', adding that the IMF report confirms that. Shadow chancellor Mel Stride said: 'Business confidence has collapsed all because of the chancellor's reckless economic choices. "You can't tax your way to growth - we need to back British businesses and workers. "Yet Rachel Reeves looks set to do it all over again in the autumn - yet more taxes, yet more pain for our economy." But Ms Reeves said the forecast still forecasts the UK to have the highest growth in the G7. The chancellor said: 'I am determined to unlock Britain's full potential, which is why we are investing billions of pounds through our Plan for Change - in jobs through better city region transport, record funding for affordable homes, as well as backing major projects like Sizewell C to drive economic growth and put more money into people's pockets.' Countries also benefited via the introduction of some higher tariff rates while others were paused until August, notably between China and the US, helping diffuse escalating trade tensions and open the door to negotiations. However, the IMF warned that a "rebound in effective tariff rates could lead to weaker growth" and weigh on wider sentiment. "Elevated uncertainty could start weighing more heavily on activity, also as deadlines for additional tariffs expire without progress on substantial, permanent agreements," the report said. Furthermore, the IMF flagged conflict in the Middle East creating potential risks to global shipping and trade, which could further raise commodity prices like oil. On the other hand, the report found that global growth could be lifted if trade negotiations lead to lower tariffs, ease tensions, and create more certainty and predictability. The IMF also highlighted technological advancements, including the use of artificial intelligence (AI), as a way to further boost growth around the world.
Yahoo
an hour ago
- Yahoo
Surging US imports and lower tariffs to lift global growth, IMF predicts
Global economic growth will be stronger than previously thought, as US imports surged and some of President Donald Trump's tariff rates have been softened since April, new projections show. Global growth is forecast to be 3% in 2025 and 3.1% in 2026, according to the International Monetary Fund's (IMF) latest World Economic Outlook. This is higher than the respective 2.8% and 3% forecast in the previous report in April. UK gross domestic product (GDP) is predicted to be 1.2% this year, and 1.4% in 2026, unchanged from revised forecasts set out in May. The upgrade to the world outlook reflects factors including a strong degree of trade 'front-loading' in recent months – referring to a rush of imports into the US. This has happened as businesses and households tried to get ahead of planned increases to US tariff rates, following Mr Trump's 'liberation day' announcements in April, according to the report. The IMF said front-loading had 'shaped economic activity in the first half of the year', adding that it was 'creating exposures that could amplify the impact of any potential negative shocks'. For example, firms could end up having too much stock, therefore pushing down future imports, or it could lead to additional holding costs or the risk of items becoming obsolete. Meanwhile, the growth upgrade since April was also driven by US tariffs being lowered since higher rates were first announced by Mr Trump, alongside improved conditions in the financial markets. This came after the US struck new trade deals, including with the UK and, most recently, the EU. The introduction of some higher tariff rates have also been paused until August, notably between China and the US, helping diffuse escalating trade tensions and open the door to negotiations. However, the IMF warned that a 'rebound in effective tariff rates could lead to weaker growth' and weigh on wider sentiment. 'Elevated uncertainty could start weighing more heavily on activity, also as deadlines for additional tariffs expire without progress on substantial, permanent agreements,' the report said. Furthermore, the IMF flagged conflict in the Middle East creating potential risks to global shipping and trade, which could further raise commodity prices like oil. On the other hand, the report found that global growth could be lifted if trade negotiations lead to lower tariffs, ease tensions, and create more certainty and predictability. The IMF also highlighted technological advancements, including the use of artificial intelligence (AI), as a way to further boost growth around the world. Chancellor Rachel Reeves said: 'The IMF's forecasts show that the UK remains the fastest growing European economy in the G7 despite the global economic challenges we are facing. 'However, I am determined to unlock Britain's full potential, which is why we are investing billions of pounds through our plan for change – in jobs through better city region transport, record funding for affordable homes, as well as backing major projects like Sizewell C to drive economic growth and put more money into people's pockets.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
an hour ago
- CNBC
CNBC Excerpts: U.S. Commerce Secretary Howard Lutnick Speaks with CNBC's 'Squawk Box' Today
WHEN: Today, Tuesday, July 29, 2025 WHERE: CNBC's "Squawk Box" Following are excerpts from the unofficial transcript of a CNBC interview with U.S. Commerce Secretary Howard Lutnick on CNBC's "Squawk Box" (M-F, 6AM-9AM ET) today, Tuesday, July 29. Following are links to video on and All references must be sourced to CNBC. LUTNICK ON EU DEAL U.S. COMMERCE SECRETARY HOWARD LUTNICK: They committed to $750 billion of energy purchases, natural gas and oil and nuclear during his term. They committed $600 billion of companies investing in America and then 15% tariffs. They will pay 15% pretty much across the board. And we, of course, have an open market to the 20 trillion, $20 trillion European market. It's five times bigger than any other, you know, Japan and India, five times bigger with 450 million people. It was a masterclass by President Trump. LUTNICK ON EU PHARMA & AUTO LUTNICK: And the key to why the Europeans did the deal is autos and pharmaceuticals. I mean, remember, we are the payor of the world, right? We all pharmaceuticals, they all make their money by selling to America. And President Trump has been very, very clear. If you're going to sell here, you're going to produce here. And so the Europeans got in front of that freight train and said, we'll pay you 15% for that, but we don't want you to rip all of our companies out of Europe and move them to America. LUTNICK ON PHARMA TARIFF POLICY LUTNICK: Pharmaceuticals was key. It was important for them to have pharmaceuticals be part of the deal at 15% because President Trump is going to come out in the next two weeks with this pharmaceutical policy, and it is going to be higher. Basically, if you are not building your plant in America where we pay for pharmaceuticals, you are going to pay a massive tariff, because why should we pay for your drugs? And you make them overseas and you make your money overseas? At least if we're going to pay for your drugs, you're going to build them in America. LUTNICK ON NATURAL RESOURCES LUTNICK: I mean, natural resources, the president did include when he does a deal, he does include if you grow something and we don't grow it, that can come in for zero. So if we do a deal with a country that grows mangoes or pineapples, then they can come in without a tariff because coffee and cocoa would be other examples of natural resource. LUTNICK ON AUGUST 1 LUTNICK: I'll leave the people who are working with China right now to, to give you a briefing on, on what they've accomplished and where they are. I'll leave it to them. But for the rest of the world, we're going to have things done by Friday. And Friday is not that far away. So you should expect, we said August 1st is the date that we're setting all these rates, and they are off to the races after that.
